Literature DB >> 15930331

Chronic lymphocytic leukemia: a niche for flavopiridol?

Jennifer R Brown1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15930331     DOI： 10.1158/1078-0432.CCR-05-0831

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  4 in total

1.  Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.

Authors:  Glen J Weiss; Manuel Hidalgo; Mitesh J Borad; Daniel Laheru; Raoul Tibes; Ramesh K Ramanathan; Lisa Blaydorn; Gayle Jameson; Antonio Jimeno; Jeffrey D Isaacs; Angela Scaburri; Maria Adele Pacciarini; Francesco Fiorentini; Marina Ciomei; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2011-12-09       Impact factor: 3.850

2.  Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

Authors:  Richard Gorlick; E Anders Kolb; Peter J Houghton; Christopher L Morton; Geoffrey Neale; Stephen T Keir; Hernan Carol; Richard Lock; Doris Phelps; Min H Kang; C Patrick Reynolds; John M Maris; Catherine Billups; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2012-02-07       Impact factor: 3.167

Review 3.  Anticancer Alkaloids from Trees: Development into Drugs.

Authors:  Tasiu Isah
Journal:  Pharmacogn Rev       Date:  2016 Jul-Dec

Review 4.  Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action.

Authors:  Paweł Łukasik; Irena Baranowska-Bosiacka; Katarzyna Kulczycka; Izabela Gutowska
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.